Friday 6 November 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
4
Average plausibility
86%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
01HealthEurope

UK doctor with Ebola treated in London; government says public risk is low

Official records and news reports support the doctor's transfer to specialist care, but the public-risk assessment comes from health authorities rather than outside testing.

BBC reports that a British doctor who tested positive for Ebola in the Democratic Republic of Congo is receiving treatment in London. The UK government says the doctor returned on a medical evacuation flight and is being cared for in the Royal Free Hospital's high-level isolation unit. Health authorities say the risk to the wider public remains low. Earlier November 4 reporting described the patient as stable while evacuation was being arranged.

What holds up

  • ✓The government’s November 5 statement confirms the positive test, completed evacuation and treatment at the Royal Free Hospital. BBC, Reuters and the Standard report the same core account, although much of their evidence comes from government statements.
  • ✓The earlier report of a stable patient has a clear basis: Reuters cited an official document on November 4, and the Guardian also reported that condition. That is evidence of the patient's reported condition then, not a current medical update.

What doesn't yet

  • ?No supplied account directly contradicts the completed transfer. Earlier descriptions of an evacuation underway concern an earlier stage, rather than evidence that the November 5 arrival reports are wrong.
  • ?The low-risk assessment belongs to UK health authorities. Several outlets repeating it do not amount to separate checks of infection-control measures; the excerpts provide no outside assessment or detailed exposure investigation.
  • ?These are snippets and excerpts, not full-article verification. They do not establish the patient's condition after the November 4 stable-condition report.

Ask before you share

  • →Has the hospital or a health authority issued a newer update on the patient's condition?
  • →What exposure checks and monitoring underpin the low-risk assessment, and have authorities reported any possible onward transmission?

Sources & original reporting

  1. [1]BBC News · Published 5 Nov 2026 · bbc.co.uk
  2. [2]Gov · Published 5 Nov 2026 · gov.uk
  3. [3]The Guardian · Published 4 Nov 2026 · theguardian.com
  4. [4]Sanluisobispo · Published 5 Nov 2026 · sanluisobispo.com
  5. [5]Standard · Published 5 Nov 2026 · standard.co.uk
  6. [6]Reuters · Published 4 Nov 2026 · rmb.reuters.com
02HealthAfrica

US-funded vaccine trial involving babies canceled in Guinea-Bissau

Reports support the cancellation of the US-funded newborn study, but withholding a birth dose is not necessarily the same as denying vaccination altogether.

BBC News reports that a proposed US-funded vaccine trial involving babies in Guinea-Bissau was canceled after criticism that its design was unethical and neocolonial. Al Jazeera identifies the vaccine as hepatitis B and reports that a researcher said the project failed to obtain necessary government approval. Channel Africa says the planned study involved 14,000 newborns, with half not receiving the recommended birth dose.

What holds up

  • ✓BBC, Al Jazeera, Channel Africa and Business Insider Africa all report that the proposed study was canceled or halted. Al Jazeera also cites a researcher acknowledging that the necessary government approval was missing, giving the cancellation claim stronger support than criticism alone.
  • ✓The newer reports consistently identify hepatitis B as the vaccine and describe withholding or delaying the newborn dose for half the participants. Al Jazeera and Channel Africa identify $1.6 million in CDC funding; Channel Africa and Business Insider Africa give a planned enrollment of 14,000.

What doesn't yet

  • ?BBC's phrase that half the babies would not receive “the vaccine” is broader than reports specifying the birth dose. Business Insider Africa describes a delay; the excerpts do not establish whether those babies would have received later doses.
  • ?MyJoyOnline reports that SDU claimed a revised protocol had ethical approval, which Nantote denied. Ethical approval and government permission may be different requirements, so this does not by itself contradict reports that the project lacked authorization.
  • ?Several accounts may draw on the same researcher statements or BBC reporting: MyJoyOnline's headline and wording closely match BBC's. Four named newsrooms reporting cancellation do not establish four separate checks, and these snippets are not full-article or trial-record verification.

Ask before you share

  • →What did the final trial protocol say about when the comparison group would receive hepatitis B vaccination?
  • →Can the government's cancellation decision and the disputed ethics approval be examined directly?
  • →Did any babies enroll or receive study treatment, and do trial records support SDU's statement that the trial never started?

Sources & original reporting

  1. [1]BBC News · Published 5 Nov 2026 · bbc.co.uk
  2. [2]Myjoyonline · Published 5 Nov 2026 · myjoyonline.com
  3. [3]Al Jazeera · Published 5 Nov 2026 · aljazeera.com
  4. [4]Channelafrica · Published 5 Nov 2026 · channelafrica.co.za
  5. [5]Africa Businessinsider · Published 5 Nov 2026 · africa.businessinsider.com
03HealthAsia-Pacific

Delhi announces winter pollution plan as experts question its adequacy

Reports support the rollout of seasonal pollution controls, while expert criticism points to problems that temporary restrictions cannot resolve.

BBC reports that Delhi's toxic winter air has returned and that the government has announced a four-month action plan. Other outlets describe measures running between November 1 and February 28, including vehicle restrictions, dust controls and higher parking charges. Experts quoted by The New York Times and The New Indian Express say temporary curbs need broader transport reforms, regional coordination and stronger local enforcement.

What holds up

  • ✓The plan's existence and broad schedule are well supported: BBC describes a four-month plan, while The Times of India reports that individual restrictions run for different periods between November 1 and February 28. The Independent quotes the chief minister's office announcing the November 1 start.
  • ✓The concern about winter air pollution extends beyond BBC's account: The New Indian Express reports deteriorating air quality, and The Times of India's headline reports an air quality index of 261 on November 1. These excerpts do not establish conditions on every subsequent day.
  • ✓Other reporting gives substance to the expert criticism. The New York Times identifies inadequate public transit and poor transportation planning, while The New Indian Express cites experts calling for action on pollution both inside and outside Delhi.

What doesn't yet

  • ?The claim that the plan 'won't be enough' is an expert assessment, not a demonstrated outcome of this winter's rollout. The excerpts provide no current evaluation showing how much pollution the new measures have reduced.
  • ?The dates describe different measures, not necessarily conflicting accounts. The Independent describes restrictions covering November through January but parking increases lasting until February 28; The Times of India explicitly says measures have different durations.
  • ?Several accounts of the rollout rely on government announcements, so repeated descriptions are not separate checks of enforcement. These snippets are not full-article verification, and they do not show whether authorities are consistently applying the rules.

Ask before you share

  • →Which restrictions are actually being enforced, and what evidence shows compliance rather than just an announced start date?
  • →How will officials measure pollution reductions while accounting for weather and pollution arriving from outside Delhi?
  • →What year-round transport and regional pollution measures will accompany the winter restrictions?

Sources & original reporting

  1. [1]BBC News · Published 5 Nov 2026 · bbc.co.uk
  2. [2]Newindianexpress · Published 26 Oct 2026 · newindianexpress.com
  3. [3]The New York Times · Published 1 Nov 2026 · nytimes.com
  4. [4]Independent · Published 1 Nov 2026 · independent.co.uk
  5. [5]Timesofindia Indiatimes · Published 1 Nov 2026 · timesofindia.indiatimes.com
04HealthAsia-Pacific

Singapore biomedical startups turn to China to develop treatments

Reports describe companies building Chinese research and manufacturing ties, but do not establish that those moves have shortened development or produced effective treatments.

CNA reports that Singapore biomedical startups are expanding into China to develop treatments for conditions including cancer and diabetes. Companies including Lion TCR and BetaLife are seeking larger patient populations, hospital partnerships and manufacturing capacity. CNA also highlights regulatory challenges, though the supplied excerpts do not explain specific rule changes or their effects.

What holds up

  • ✓The expansion has concrete company examples behind it. Earlier background reporting from The Business Times describes Lion TCR’s Chinese hospital ties and manufacturing facilities, while ThinkChina reports that BetaLife established joint ventures in Shenzhen and Xiamen in September 2025.
  • ✓CNA’s news excerpt and radio discussion both identify access to patients, clinical partners and manufacturing as reasons for entering China. The Business Times’ background account supports those reasons for Lion TCR, though company statements do not prove that development has actually become faster.

What doesn't yet

  • ?The excerpts provide no trial results, approval records or before-and-after development timelines. Faster development is a stated aim, not a demonstrated outcome; CNA’s warning about evolving regulations also lacks specific examples here.
  • ?Source breadth is limited: the evidence used comes from three original reporting outlets, so other accounts may be missing. CNA’s radio and news coverage are from the same newsroom, and UA News explicitly repeats CNA’s BetaLife reporting rather than supplying a separate check. These excerpts are not full-article verification.

Ask before you share

  • →Which trials have received authorization, started enrolling patients or published results, and have Chinese partnerships measurably shortened their timelines?
  • →Which Chinese regulatory changes affect these companies, and what do they mean for trial oversight, manufacturing standards and eventual approval elsewhere?

Sources & original reporting

  1. [1]CNA · Published 6 Nov 2026 · channelnewsasia.com
  2. [2]Channelnewsasia · Published 3 Nov 2026 · channelnewsasia.com
  3. [3]Ua · Published 6 Nov 2026 · ua.news
  4. [4]Businesstimes · Published 26 Oct 2026 · businesstimes.com.sg
  5. [5]Thinkchina · Published 21 Oct 2026 · thinkchina.sg